ClinicalTrials.gg
Not yet recruitingNCT07949045EPIDOCAVILHUpdated Nov 19, 2026

Evaluation of a City-hospital Pathway for Early Management of Acute Pain in Oncology

An interventional study of Questionnaire and Physical Exam in Gynecologic Cancers, Digestive Cancers and Urological Cancer, sponsored by Poitiers University Hospital. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Poitiers University Hospital · Not applicable, Interventional, and Health services research

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

In France, the number of new cancer cases across all cancer types was estimated at 382,000 in 2018. The impact of pain on a patient's quality of life is profound, with physical consequences (insomnia, fatigue, loss of appetite), psychological effects (anxiety, depression, demoralization, attention deficit, memory disorders), and social repercussions.

Acute pain induced by cancer, when poorly managed, can lead to the development of secondary chronic pain syndrome. The French National Authority for Health (Haute Autorité de Santé, HAS) deplores the late referral of patients with chronic pain, which complicates treatment and limits opportunities for improvement. Cancer-related pain has become a chronic condition in 50% of patients, leading to anxiety-depressive syndromes as well as social consequences such as social isolation or difficulty returning to professional activity.

In France, the 2017 White Paper by the SFETD (French Society for the Study and Treatment of Pain) notes that, despite three successive Cancer Plans integrating supportive care into the comprehensive management of cancer patients, one in three patients does not receive analgesic treatment appropriate to the intensity of their pain. To prevent chronic pain, the HAS recently recommended early assessment of acute pain (within less than a week) with a high-quality city-hospital organization.

Read the detailed description

This study proposes a systematic care pathway for the evaluation and treatment of pain in patients experiencing pain symptoms at the time of cancer diagnosis or relapse. A multidimensional pain assessment consultation will be conducted within 48 hours, along with the implementation of appropriate treatment. The patient will receive therapeutic education for self-assessment of pain, enabling the general practitioner to adjust analgesic treatments on an outpatient basis. The relevance of this pathway lies in the systematic assessment of pain and close collaboration between the general practitioner and the hospital, coordinated by a pain specialist. The general practitioner, who has an in-depth knowledge of the patient, should remain the primary coordinator of the patient's health pathway.

02

Conditions studied

  • Gynecologic Cancers
  • Digestive Cancers
  • Urological Cancer
  • Hematological Cancers

Keywords

  • cancer
  • pain management
03

In context

Gastrointestinal Neoplasms

697 studies on the registry are indexed under Gastrointestinal Neoplasms; 210 are open to participants now.

This study's planned enrollment of 30 is below the median of 74 across 496 interventional studies indexed under Gastrointestinal Neoplasms.

Browse Gastrointestinal Neoplasms studies →

Lead sponsor

Poitiers University Hospital is the lead sponsor of 315 studies on the registry; 63 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Patient ≥ 18 years old.
  • Consultation for treatment initiation ( or relapse) for gynecological, digestive, urological, or hematological cancer.
  • Patient experiencing pain related to a cancer pathology (pain numerical rating scale ≥ 1) for less than 3 months.
  • Patient receiving outpatient cancer treatment at the Châtellerault site of Poitiers University Hospital.
  • Patient declaring having a general practitioner.
  • Patient's general practitioner agreeing to participate in the study.
  • Patient covered by the French social Security system or through a third party.

Non-Inclusion Criteria:

  • Patient already receiving care for this pain from the reference pain center or supportive care team.
  • Patient unable to understand, write, or speak French.
  • Patient diagnosed with uncontrolled psychiatric disorders.
  • Patient with chronic pain unrelated to cancer.
  • Pain related to therapeutic procedures.
  • Patient residing in a medicalized facility.
  • Patient under enhanced protection, including: minors, pregnant or breastfeeding women, individuals deprived of liberty by judicial or administrative decision, individuals staying in a healthcare or social institution, adults under legal protection (guardianship, curatorship, or subordination), patients in emergency situations.
  • Patient with a significant impairment of general condition (-PS > 2, Eastern Cooperative Oncology Group Performance Status) or cognitive disorders.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Early management of acute pain

    Day 0: Multidimensional pain assessment (MPA) consultation conducted by a qualified paramedical professional (QPP) within 48 hours following the oncology consultation. Multidimensional pain will be evaluated using the Brief Pain Inventory-Short Form (BPI-SF). The QPP transfers a report of this assessment to the general practitioner of the patient. Appropriate treatment of pain is implemented by the QPP. Day 2: Consultation with the general practitioner. Based on the report send by the QPP at day 0 and with the self-administration of the BPI-SF fulfilled by the patient at day 2, the general practitioner adjusts pain-relieving treatments if necessary. Day 7: MPA consultation conducted by the QPP who transfers a report of the BPI-SF assessment to the general practitioner. If the patient reports pain symptoms at day 7, then consultation with the general practitioner and MPA consultation are repeated ever week until resolution of pain symptoms.

    Other: Questionnaire and Physical Exam

Interventions

  • OtherQuestionnaire and Physical Exam

    Brief Pain Inventory-Short Form is performed twice every week (for the multidimensional pain assessment consultation and for the general practitioner consultation) until resolution of the pain symptoms or up to day 28 (end of the study).

06

What researchers measure

Primary outcomes

  1. Proportion of eligible patients that provide a consent to participate

    Patient's acceptability will be assessed if ≥ 80% of the eligible patients provide a signed consent.

    Time frame: 1 day

  2. Proportion of general pactitioner that confirmed their participation

    General practitioner's acceptability will be assessed if ≥80% of the practitioners related to the eligible patients confirmed their participation.

    Time frame: 2 days

  3. Proportion of consultations with the general practitioner performed

    Completion of consultations with the general practitioner will be assessed if ≥ 80% of the consultations with the general practitioner recommended by the pathway are completed.

    Time frame: 28 days

  4. Proportion of consultations at the hospital performed

    Completion of consultations at the hospital will be assessed if ≥ 80% of the consultations at the hospital recommended by the pathway are completed.

    Time frame: 28 days

Secondary outcomes

  1. Change in pain severity after 28 days

    Pain severity is assessed using the dimension "pain severity" of the Brief Pain Inventory-Short Form (BPI-SF). Change in pain severity is defined as the difference of the two scores assessed at day 0 and at day 28. Pain severity score ranges from 0 (no pain) to 10 (severe pain).

    Time frame: 28 days

  2. Change in pain interference after 28 days

    Pain interference is assessed using the dimension "pain interference" of the Brief Pain Inventory-Short Form (BPI-SF). Change in pain interference is defined as the difference of the two scores assessed at day 0 and at day 28. Pain interference score ranges from 0 (no pain) to 10 (severe pain).

    Time frame: 28 days

  3. Change in quality of life after 28 days

    Quality of life is assessed using the EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer, Quality of Life Core Questionnaire). Change in quality of life is defined as the difference of the global quality of life scores assessed at day 0 and at day 28. Quality of life score ranges from 0 (worst quality of life) to 100 (best quality of life).

    Time frame: 28 days

  4. Proportion of patients requiring a specific pain management

    Specific pain management includes: hospitalization due to the pain, referral to a pain management center, or referral to a mobile palliative care team.

    Time frame: 28 days

  5. Global satisfaction of the patients

    Satisfaction of the patient will be assessed using a 5-point Likert scale (0 anchored with "not satisfied at all" and 4 anchored with "very satisfied")

    Time frame: 28 days

  6. Proportion of patients with a modified prescription by the general practitioner for analgesics treatments

    The proportion of patients with a new analgesic treatment added or with a dose escalation or a dose reduction or a therapeutic switch

    Time frame: 28 days

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Jan 2028, 12 months later.

Of 154 non-industry interventional studies with no phase under Gastrointestinal Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 71. This study's planned 12 months is below that.

Counting every sponsor, half of 164 studies reached it within 36 months; a quarter within 17 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2026
First posted
Nov 19, 2026
StartEst.
Jan 1, 2027
Primary completionEst.
Jan 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07949045
Responsible party
Sponsor
First posted
Nov 19, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Jan 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 19, 2026

Study contacts

MAUD BRECHET
Contact
MAUD.BRECHET@chu-poitiers.fr
0033549029991
STEPHANIE NOEL
Contact
stephanie.noel@chu-poitiers.fr
0033549443083

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion